胰高血糖素样肽-1改善非酒精性脂肪肝病作用机制的研究进展

非酒精性脂肪肝病（nonalcoholic fatty liver disease，NAFLD）与肥胖、胰岛素抵抗、2型糖尿病和血脂紊乱等密切相关。随着肥胖和糖尿病的发病率逐渐升高，NAFLD已成为全球最常见的慢性肝脏疾病。目前，NAFLD的主要治疗方法为改善生活方式、减轻体质量和应用降脂药物，尚缺乏特效的治疗药物。靶向胰高血糖素样肽-1（glucagon-like peptide-1，GLP-1）已被批准用于糖尿病和肥胖治疗，最近大量临床前和临床研究表明，GLP-1可通过多种机制缓解NAFLD。本文将GLP-1改善NAFLD的相关机制研究进展综述如下。

Progress of mechanisms of glucagon-like peptide-1 in ameliorating nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease (NAFLD) is closely associated with obesity, insulin resistance, type 2 diabetes mellitus, and lipid disorders. With the growing incidence of obesity and diabetes, NAFLD has become the most common chronic liver disease worldwide. At present, the treatment of NAFLD is mainly limited to lifestyle intervention, reduction of weight, and use of lipid-lowering drugs, but there is no specific drug for NAFLD. Glucagon-like peptide-1 (GLP-1) has been approved for diabetes and obesity, and numerous clinical and preclinical studies have shown that GLP-1 could alleviate NAFLD by multiple mechanisms. In this paper, the mechanisms of GLP-1 in improving NAFLD are summarized as follows.